US stocks drift ahead of Tuesday's jobs report
THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below.
The S&P 500 slipped 0.2%, even though a slight majority of stocks within the index rose. The Dow Jones Industrial Average was down 75 points, or 0.2%, as of
Helping to keep the market in check were stocks in the artificial-intelligence industry, which were mixed following their scary swings last week.
But Oracle sank another 2.6% following its 12.7% tumble last week, which was its worst in more than seven years.
AI stocks have been shaky on worries that the billions of dollars flowing into chips and data centers may not produce a big-enough payoff to make it worth it. The doubts are causing cracks for the industry, whose earlier surges was the main driver for the
Besides AI, the main focus on
On Tuesday will come the jobs report for November, and economists expect it to show employers added 40,000 more jobs than they cut during the month. Thursday will bring an update on the inflation, and economists expect it to show
Such data is under the microscope because the
The hope on
“With the Fed still appearing to be more focused on labor-market weakness than inflation, we’re likely facing a ‘bad news is good’ scenario for the jobs report,” according to
“As long as the numbers don’t suggest employment is falling off a cliff,” that would mean the market would likely welcome soft numbers, he said.
The spotlight will be brightest on the unemployment rate, not the overall job growth numbers, because the latter is feeling downward pressure from a drop-off in immigrant workers. Economists expect Tuesday’s report to show the unemployment rate at 4.4%, which would keep it near its highest and worst level since 2021.
The yield on the 10-year
Elsewhere on
In stock markets abroad, indexes rose in
Indexes fell 1.3% in
Japan’s
___
AP Business Writer


Legislation introduced to extend national flood insurance program
Report Summarizes Kinase Inhibitors Study Findings from Saga University Hospital (Simulation of Perioperative Ibrutinib Withdrawal Using a Population Pharmacokinetic Model and Sparse Clinical Concentration Data): Drugs and Therapies – Kinase Inhibitors
Advisor News
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
- Semi-retirement: helping clients balance flexibility with financial security
More Advisor NewsAnnuity News
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
- Jackson Launches Direct-to-Consumer Annuity Offering
- Global Atlantic launches ForeIncome Flex
- Athene CEO criticizes offshore reinsurance, risk-taking by competitors
- DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
More Annuity NewsHealth/Employee Benefits News
- WHITEHOUSE, WYDEN, OSSOFF DEMAND BIG HEALTH INSURANCE CEOS DELIVER ON PROMISES TO REDUCE PATIENT CARE DELAYS
- Medicaid work rules don’t apply to Native Americans. They could still lose coverage.
- Oscar Highlights Tailored New Health Products in Florida for 2027 Open Enrollment
- Oscar Highlights Tailored New Health Products in Texas for 2027 Open Enrollment
- States get until July to cut Medicaid coverage over work requirement
More Health/Employee Benefits NewsLife Insurance News
- Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
- Military Briefs: November 19-25
- California’s new solvency rules: What should life insurance advisors watch?
- Navigating delayed death certificates: A guide for life insurance advisors
- Jackson Launches Direct-to-Consumer Annuity Offering
More Life Insurance News